<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905511</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-001</org_study_id>
    <nct_id>NCT04905511</nct_id>
  </id_info>
  <brief_title>Preliminary Safety of The TRUE Vascular Graft for Hemodialysis Access (TRUE HD I Study)</brief_title>
  <official_title>Preliminary Safety of The TRUE Vascular Graft for Hemodialysis Access (TRUE HD I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascudyne, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascudyne, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, nonrandomized, single-arm, single-center, open-label, first-in-human clinical&#xD;
      study in subjects with end-stage renal disease (ESRD) and not candidates for an autogenous&#xD;
      fistula creation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, nonrandomized, single-arm, single-center, open-label, first-in-human clinical&#xD;
      study in subjects with end-stage renal disease (ESRD) and not candidates for an autogenous&#xD;
      fistula creation. Subjects will be followed regularly with office visits at the&#xD;
      investigational site at days 15, 29, 57 and weeks 12, 26 for vessel imaging, blood draws and&#xD;
      other follow-up tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, nonrandomized, single-arm, single-center, open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, adverse events</measure>
    <time_frame>26 weeks</time_frame>
    <description>incidence of clinically significant aneurysm, anastomotic bleeding, graft or anastomotic rupture, graft infection, and implant site irritation, inflammation, or infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patency</measure>
    <time_frame>26 weeks</time_frame>
    <description>time to loss of patency from implantation by Kaplan Meier</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunology</measure>
    <time_frame>baseline through 4 weeks</time_frame>
    <description>assess changes in panel reactive antibody (PRA) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention rate</measure>
    <time_frame>through 26 weeks</time_frame>
    <description>rate of interventions needed to maintain patency</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>TRUE Vascular Graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be implanted with the TRUE Vascular Graft in the upper arm or forearm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>natural human collagen arteriovenous graft for hemodialysis access</intervention_name>
    <description>The True Vascular Graft will be implanted in the forearm or upper arm in a straight or curved configuration.</description>
    <arm_group_label>TRUE Vascular Graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with end stage renal disease (ESRD) who are not, or who are no longer,&#xD;
             candidates for creation of a simple autogenous AV fistula (radio-cephalic or&#xD;
             brachio-cephalic without requiring transposition) and therefore need placement of an&#xD;
             AV graft in the upper extremity to start or maintain hemodialysis therapy.&#xD;
&#xD;
          -  Either on hemodialysis or expected to start hemodialysis within 12 weeks of study&#xD;
             conduit implantation.&#xD;
&#xD;
          -  Patients between 18 and 75 years old, inclusive.&#xD;
&#xD;
          -  Life expectancy of at least 1 year.&#xD;
&#xD;
          -  Negative COVID-19 test within 3 days prior to surgery and negative for symptoms within&#xD;
             14 days prior to surgery.&#xD;
&#xD;
          -  Able to communicate meaningfully with investigative staff and able to comply with&#xD;
             entire study procedures.&#xD;
&#xD;
          -  Willing and competent to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or evidence of severe cardiac disease (NYHA Functional Class III or IV),&#xD;
             myocardial infarction within six months prior to study entry (Day 1), ventricular&#xD;
             tachyarrhythmias requiring continuing treatment, or unstable angina.&#xD;
&#xD;
          -  Uncontrolled or poorly controlled diabetes; hospitalization for poor glucose control&#xD;
             within the previous 6 months.&#xD;
&#xD;
          -  History or evidence of severe peripheral vascular disease in the upper limbs&#xD;
&#xD;
          -  Known or suspected central vein obstruction on the side of planned graft implantation.&#xD;
&#xD;
          -  Documented hypercoagulable state or history of thromboembolic events or history of&#xD;
             repeated venous catheter clotting.&#xD;
&#xD;
          -  Known Positive COVID 19 test result or known exposure to COVID 19 in past 4 months.&#xD;
&#xD;
          -  Known active infection including dental infection, osteomyelitis and other conditions&#xD;
             which could present a local or systemic risk of infection.&#xD;
&#xD;
          -  Bleeding diathesis.&#xD;
&#xD;
          -  Contraindication to or known serious allergy to anticoagulant, aspirin, or planned&#xD;
             antiplatelet therapy. History of heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Contraindication to or known serious allergy to penicillin.&#xD;
&#xD;
          -  Ongoing therapy with vitamin K antagonists or direct thrombin inhibitors or factor Xa&#xD;
             inhibitors.&#xD;
&#xD;
          -  Immunodeficiency including AIDS / HIV or active autoimmune disease, or on&#xD;
             immunosuppressant therapy.&#xD;
&#xD;
          -  Previous PTFE graft in the operative limb unless the TRUE graft can be placed more&#xD;
             proximally than the previous failed graft.&#xD;
&#xD;
          -  More than 1 failed PTFE graft in the operative limb.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Ebner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanatorio Italiano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Stenoien</last_name>
    <phone>7632031032</phone>
    <email>mstenoien@vascudyne.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sanatario Italiano</name>
      <address>
        <city>Asunci√≥n</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Ebner, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Paraguay</country>
  </location_countries>
  <reference>
    <citation>Syedain ZH, Graham ML, Dunn TB, O'Brien T, Johnson SL, Schumacher RJ, Tranquillo RT. A completely biological &quot;off-the-shelf&quot; arteriovenous graft that recellularizes in baboons. Sci Transl Med. 2017 Nov 1;9(414). pii: eaan4209. doi: 10.1126/scitranslmed.aan4209.</citation>
    <PMID>29093182</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

